High-Tech Gründerfonds has provided seed financing for Immunservice GmbH, a start-up which develops immune biomimetic hormones for drug testing. The seed financing enables the company to optimise production of its lead product Pulmoleukin to industrial scale and to prepare the approval process of the drug. In addition to the seed funding, the company received grants, and more capital will be raised in a further funding round that has already attracted interest from international co-investors.
Charcoal and natural additives company saw final bids from two banks and one direct lender
VCs including the Swiss Entrepreneurs Fund, BtoV and Ringier Digital Ventures also participated
Around 40 existing and new LPs, including British Patient Capital and the EIF, participated
Fund will invest in buyouts, recapitalisations and carve-outs of both profitable and underperforming businesses